ArticleJournal of clinical research in pediatric endocrinology2026
The Course of Progranulin Levels at Admission and During Early Period of Insulin Treatment in Children with Newly Diagnosed Type 1 Diabetes Mellitus
Article in Journal of clinical research in pediatric endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Progranulin (PGRN), a growth factor, modulates cell proliferation, wound repair, and inflammation. It is also involved in glucose metabolism and is associated with insulin resistance and diabetes mellitus (DM). In the present study, PGRN levels were measured at admission and during follow-up in children with newly diagnosed type 1 DM (T1DM) and compared to healthy controls. Methods: Children with T1DM and healthy controls were included. The age, weight, height, body mass index (BMI), severity of acidosis, glucose, insulin, C-peptide, and diabetes-specific autoantibodies of children with newly diagnosed T1DM were collected. PGRN was measured in children with T1DM at admission, at first week of follow-up, and in healthy controls. Results: A total of 49 children were included; 25 with T1DM [12 Female/13 Male (12F/13M)] and 24 healthy controls (10F/14M). There was no differences in age (11±3.9 years vs 12.1±3.1 years, p=0.269) and BMI standard deviation (SD) score (-0.11±1.49 SD vs. 0.10±0.82 SD, p=0.540) of children with T1DM and healthy controls. The mean basal PGRN level of children with newly diagnosed T1DM was higher than in controls (90.8±17.3 ng/mL vs. 30±11.5 ng/mL, p<0.001). In children with T1DM, mean basal PGRN at admission had declined significantly (58.4±16.9 ng/mL; p<0.001) in the first week after glycemic regulation was achieved but remained significantly higher than in controls (p<0.001). Conclusion: These findings suggest that elevated PGRN levels in children with newly diagnosed T1DM may reflect either an acute inflammatory response to diabetic ketoacidosis or a persistent alteration in metabolic regulation, or both of these, highlighting the potential role of PGRN as a biomarker in the early course of T1DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.